Correlation between fecal (calprotectin and lactoferrin) results and   colonoscopic findings in chronic diarrhea and recurrent abdominal pain in children and adolescents

Raafat Abdel-Raouf Muhammad Khattab; Hany Ali Hussien Samy; Ahmed Helal El Sayed; Ahmed Ali Ali Assem; Mohammed Sobhy Mohammed Mansour

doi:10.53730/ijhs.v6nS1.6782

Authors

Raafat Abdel-Raouf Muhammad Khattab Pediatric department, Faculty of Medicine, Al-Azhar University, Egypt
Hany Ali Hussien Samy Pediatric department, Faculty of Medicine, Al-Azhar University, Egypt
Ahmed Helal El Sayed Pediatric department, Faculty of Medicine, Al-Azhar University, Egypt
Ahmed Ali Ali Assem Clinical Pathology department, Faculty of Medicine, Al-Azhar University, Egypt
Mohammed Sobhy Mohammed Mansour
mohammedmansour908@gmail.com
Pediatric department, Faculty of Medicine, Al-Azhar University, Egypt

Keywords:

abdominal pain, chronic diarrhea, endoscopy, fecal calprotectin, lactoferrin inflammatory bowel disease

Abstract

Background: Currently, endoscopy with biopsy is still considered the gold standard for the evaluation and diagnosis of mucosal inflammation and a number of scores exist to assess endoscopic activity in Crohn’s disease (CD) and ulcerative colitis (UC). Aim and objectives: the aim of the study was to determine the benefit of using both of fecal markers (calprotectin and lactoferrin) in patients presenting with chronic diarrhea and recurrent abdominal pain for differentiation between organic diseases, particularly inflammatory bowel disease (IBD) from non-organic disease, making colonoscope unnecessary. Subjects and methods: This prospective, observational and analytic study was carried out on 44 children who fulfilling the designed inclusion criteria. The study was carried out from Outpatient Clinic of Pediatric gastroenterology unit and from the Inpatient Units of the Pediatric department Faculty of Medicine, Al-Azhar University Hospitals (Al-Hussein & Sayed Galal Hospitals), as well as referral from other hospitals complaining of recurrent abdominal pain and chronic diarrhea from March 2020 to March 2022. Results: there was statistically significant difference between IBD group and functional abdominal pain group as regard fecal calprotectin with p-value≤ 0.001. There was statistically significant difference between IBD group and functional abdominal pain group as regard fecal lactoferrin with p-value≤ 0.001.

Downloads

Download data is not yet available.

References

Schiller LR, Pardi DS, Sellin JH. Chronic Diarrhea: Diagnosis and Management. Clin. Gastroenterol. Hepatol. 2017; 15(2):182-193.e3.

Friesen C, Colombo JM, Deacy A, Schurman, JV. An Update on the Assessment and Management of Pediatric Abdominal Pain. Pediatric Health, Medicine and Therapeutics, 2021; 12, 373.‏

Yarger E, Sandberg K. Updates in diagnosis and management of chronic abdominal pain. Current Problems in Pediatric and Adolescent Health Care, 2020; 50(8): 100840.‏

Di Lorenzo C, Colletti RB, Lehmann HP. AAP Subcommittee; NASPGHAN Committee on Chronic Abdominal Pain. Chronic abdominal pain in children: a technical report of the American Academy of Pediatrics and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2005; 40(3):249–261.

Weimers P, Halfvarson J, Sachs MC, Saunders-Pullman R, Ludvigsson JF, Peter I, et al. Inflammatory bowel disease and Parkinson’s disease: a nationwide Swedish cohort study. Inflammatory bowel diseases, 2019; 25(1): 111-123.

Carroll MW, Kuenzig ME, Mack DR, Otley AR, Griffiths AM, Kaplan GG, et al. The impact of inflammatory bowel disease in Canada 2018: children and adolescents with IBD. Journal of the Canadian Association of Gastroenterology, 2019; 2(Supplement_1): S49-S67.‏

Iwanczak B, Iwanczak F. Indicators of inflammatory process in stool in diagnostics and monitoring of inflammatory bowel diseases. Pol Merkur Lekarski. 2015; 39: 389-392.

Holtman GA, Lisman-van Y, Day AS, Fagerberg UL, Henderson P, Leach ST, et al. Use of Laboratory Marker in Addition to Symptoms for Diagnosis of Inflammatory Bowel Disease in Children: A Meta-analysis of Individual Patient Data. JAMA Pediatr. 2017; 171:984-991.

Buderus S, Boone JH, Lentze MJ. Fecal Lactoferrin: Reliable Biomarker for Intestinal Inflammation in Pediatric IBD. Gastroenterol. Res. Pract. 2015; 1–4. doi: 10.1155/2015/578527.

Dai C, Jiang M, Sun MJ. Fecal markers in the management of inflammatory bowel disease. Postgraduate Medicine, 2018; 130(7): 597-606.‏

Varni JW, Bendo CB, Nurko S. Health-related quality of life in pediatric patients with functional and organic gastrointestinal diseases. J Pediatr. 2015; 166(1):85–90.

Brusaferro A, Farinelli E, Zenzeri L, Cozzali R, Esposito S. The management of paediatric functional abdominal pain disorders: latest evidence. Pediatric drugs, 2018; 20(3): 235-247.‏

Gearry RB, Richardson AK, Frampton CM, Dodgshun AJ, Barclay ML. Population‐based cases control study of inflammatory bowel disease risk factors. Journal of gastroenterology and hepatology, 2010; 25(2), 325-333.

Khalil AF, Helmy EM, Massoud MN, Baddour NM, Metwally RH, Omar OM. Does faecal calprotectin differentiate between inflammatory bowel disease colitis and non-inflammatory bowel disease colitides?. Przegla̜d Gastroenterologiczny, 2021; 16(3), 219.‏

Degraeuwe PL, Beld MP, Ashorn M, Canani RB, Day AS, Diamanti A, et al. Faecal calprotectin in suspected paediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2015; 60(3):339–46.

Henderson P, Anderson NH, Wilson DC. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2014; 109(5): 637–45.

Nasser A, Akam D, Eman A. Role of Fecal Calprotectin and Lactoferrin as Biomarkers of Intestinal Inflammation in Ulcerative Colitis. Available at: Users/ Elbinawi/ Downloads/ fecalcalprotectinin Ucolitis Alexandria Journal of Hepatogastroenterology Volume XXI-December, 2016.

Lamb CA, Mohiuddin MK, Gicquel J. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br J Surg, 2009; 96: 663–74.

Pieczarkowski S, Kowalska-Duplaga K, Kwinta P, Tomasik P, Wędrychowicz A, Fyderek, K. Diagnostic value of fecal calprotectin (S100 A8/A9) test in children with chronic abdominal pain. Gastroenterology research and practice, 2016.

Tavabie OD, Hughes SA, Loganayagam A. The role of faecal calprotectin in the differentiation of organic from functional bowel disorders. Br J Gen Pract. 2014; 64(628): 595–6.

Van de Vijver E, Schreuder AB, Cnossen WR, Muller Kobold AC, van Rheenen PF. Safely ruling out inflammatory bowel disease in children and teenagers without referral for endoscopy. Arch Dis Child. 2012; 97(12):1014–8.

Sipponen T, Kolho K. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand J Gastroenterol. 2015; 50(1): 74–80.